Real-World Comparative Effectiveness of First-Line Dabrafenib Plus Trametinib Versus Immunochemotherapy in Patients with Advanced BRAF V600-Mutant Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
Haizhou Yue, Qianxin Zhou, Suyu Wang, Shuangyi Li, Junyi Li, Huanzhi La, Shuyan Meng · 2026
Read Real-World Comparative Effectiveness of First-Line Dabrafenib Plus Trametinib Versus Immunochemotherapy in Patients with Advanced BRAF V600-Mutant Non-Small-Cell Lung Cancer: A Retrospective Cohort Study by Haizhou Yue, Qianxin Zhou, Suyu Wang, Shuangyi Li, Junyi Li, Huanzhi La, Shuyan Meng (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13566382.txt.
Description
Haizhou Yue and six co-authors compared two first treatments for advanced lung cancer carrying a BRAF V600 mutation, using real hospital records, in a 2026 study. The choice between a targeted drug pair, dabrafenib plus trametinib, and immunotherapy combined with chemotherapy was unsettled. The single-center study covered 142 patients treated from 2017 to 2024.
In raw comparisons, the targeted pair kept cancer at bay far longer, a median of 32.5 months against 13.3. After matching patients to balance the groups, the gap narrowed to 19.6 against 12.6 months and was no longer statistically firm. Adjusted models still favored the targeted pair over every other regimen. Overall survival did not differ significantly.
Catalog record
| CREATOR | Haizhou Yue, Qianxin Zhou, Suyu Wang, Shuangyi Li, Junyi Li, Huanzhi La, Shuyan Meng |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |